{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:02:11Z","timestamp":1784901731815,"version":"3.55.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Spinal involvement is common in Duchenne muscular dystrophy (DMD), specifically scoliosis and vertebral fractures. Treatment with corticosteroids (CS) delays scoliosis onset, but also induces low bone mineral density, increasing fracture risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess long-term effects of intermittent CS on scoliosis development, bone mineral density and vertebral fractures in DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We retrospectively analysed real-world data from a single national reference center in the Netherlands. Spinal imaging was obtained by yearly anteroposterior radiographs. Scoliosis was defined as lateral spinal curvature with a Cobb angle of &gt;10\u00b0. Yearly lumbar spine bone mineral density (LSBMD) Z-scores were measured with dual-energy X-ray absorptiometry (DXA) scans of the lumbar spine. Vertebral fractures were evaluated using yearly vertebral fractures assessments (VFA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 86 individuals with DMD who visited the outpatient clinic between 2002 and 2022, aged 4-18 years. Seventy-five patients (87.2%) developed scoliosis (median age 11.0 years), mostly after loss of ambulation. Scoliosis progressed to &gt;20\u00b0 in 40 (46.5%) and to &gt;30\u00b0 in 29 (33.7%) of all patients. Spinal fusion was performed in 20 (23.3%) of all patients (median age 18.5 years). Cobb angles significantly increased after loss of ambulation (LoA) (p&lt;0.001).<\/jats:p>\n                    <jats:p>Mean height SDS was -0.8. LSBMD Z-score declined below -2.0 in 27 (31.4%) patients and was significantly lower after LoA (p&lt;0.001). Of 86 patients, 64 underwent VFAs, with 16 (25%) developing vertebral fractures during follow-up, mostly asymptomatic (87.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals with DMD on intermittent CS experience a higher incidence of scoliosis, fewer vertebral fractures, and generally maintain higher LSBMD Z-scores compared to published data on patients receiving daily CS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602261472975","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:11:24Z","timestamp":1784898684000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of intermittent corticosteroids on scoliosis, bone density, and vertebral fractures in duchenne muscular dystrophy"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0609-4752","authenticated-orcid":false,"given":"Nadine A.","family":"Ikelaar","sequence":"first","affiliation":[{"name":"Leiden University Medical Center"},{"name":"Duchenne Center Netherlands, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9392-8167","authenticated-orcid":false,"given":"Louise S. M.","family":"Blok","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2202-5227","authenticated-orcid":false,"given":"Mees H. P.","family":"Stoop","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne D.","family":"Krom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"},{"name":"Duchenne Center Netherlands, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bongers","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8270","authenticated-orcid":false,"given":"Petra","family":"Dibbets-Schneider","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"van Zwet","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Bas","family":"de Witte","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-5143","authenticated-orcid":false,"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center"},{"name":"Duchenne Center Netherlands, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001950"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.05.003"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70272-8"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.21037\/jss.2016.08.05"},{"key":"e_1_3_7_7_2","first-page":"142","article-title":"Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy","volume":"10","author":"Ward LM","year":"2018","unstructured":"Ward LM, Hadjiyannakis S, McMillan HJ, et al. Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics 2018; 10: 142. https:\/\/doi.org\/10.1542\/peds.2018-0333E","journal-title":"Pediatrics"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170280"},{"key":"e_1_3_7_11_2","first-page":"1607","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King WM","year":"2007","unstructured":"King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007\u201305\u201308 2007; 68: 1607\u20131613. https:\/\/doi.org\/10.1212\/01.wnl.0000260974.41514.83","journal-title":"Neurology 2007\u201305\u201308"},{"key":"e_1_3_7_12_2","first-page":"95","article-title":"Glucocorticoid Treatment for the Prevention of Scoliosis in Children with Duchenne Muscular Dystrophy: Long-Term Follow-up","volume":"19","author":"Lebel DE","year":"2013","unstructured":"Lebel DE, Corston JA, McAdam LC, et al. Glucocorticoid Treatment for the Prevention of Scoliosis in Children with Duchenne Muscular Dystrophy: Long-Term Follow-up. JBJS June 2013; 19: 95\u20131061. https:\/\/doi.org\/10.2106\/JBJS.L.01577","journal-title":"JBJS June"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1443-y"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0242"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.07.019"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303902"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0170"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000000817"},{"issue":"6","key":"e_1_3_7_19_2","first-page":"35","article-title":"Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy","volume":"35","author":"Zhou L","year":"2024","unstructured":"Zhou L, Zhou H, Xu H, et al. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy. Osteoporosis International 2024; 35(6): 35\u20131005. https:\/\/doi.org\/10.1007\/s00198-024-07018-3","journal-title":"Osteoporosis International"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-240061"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2012.189"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2004.tb00508.x"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1111"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650080915"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.04.003"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0012162206001083"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1302\/1863-2548.14.200156"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2006.12.002"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2013.09.034"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.19.2917"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01241398-200001000-00016"},{"key":"e_1_3_7_32_2","first-page":"15","article-title":"Poor bone health in Duchenne muscular dystrophy: a multifactorial problem beyond corticosteroids and loss of ambulation","volume":"28","author":"Hurley-Novatny A","year":"2024","unstructured":"Hurley-Novatny A, Chang D, Murakami K, et al. Poor bone health in Duchenne muscular dystrophy: a multifactorial problem beyond corticosteroids and loss of ambulation. Frontiers in Endocrinology 2024; 28: 15. https:\/\/doi.org\/10.3389\/fendo.2024.1398050","journal-title":"Frontiers in Endocrinology"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07681-0"},{"issue":"1","key":"e_1_3_7_34_2","first-page":"34","article-title":"Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy","volume":"34","author":"Phung K","year":"2022","unstructured":"Phung K, McAdam L, Ma J, et al. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy. Osteoporosis International 2022; 34(1): 34\u2013160. https:\/\/doi.org\/10.1007\/s00198-022-06578-6","journal-title":"Osteoporosis International"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.01.006"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07651-6"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.05.012"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-016-4556-3"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"e_1_3_7_40_2","first-page":"102","article-title":"Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence","volume":"102","author":"Landfeldt E","year":"2023","unstructured":"Landfeldt E, Phung K, Zaman F, et al. Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence. Neurology 2023; 102: 102. https:\/\/doi.org\/10.1212\/WNL.0000000000207948","journal-title":"Neurology"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602261472975","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602261472975","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602261472975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:11:25Z","timestamp":1784898685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602261472975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":39,"alternative-id":["10.1177\/22143602261472975"],"URL":"https:\/\/doi.org\/10.1177\/22143602261472975","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"22143602261472975"}}